Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma

This study tests whether giving immunotherapy (anti-PD-1 or anti-CTLA-4 drugs) as part of a "conversion therapy" approach — to shrink initially inoperable liver cancer enough so it can then be surgically removed — is effective and safe. **You may be eligible if...** - You are 18 or older - You have confirmed advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed - You have at least one measurable tumor - You have not received any prior immunotherapy - Your overall health status is acceptable (ECOG 0–2) - Your liver function is acceptable (Child-Pugh grade A or B) **You may NOT be eligible if...** - You have a history of immune deficiency or autoimmune disease - You have another active cancer - You previously received immunotherapy (PD-1 or CTLA-4 blocking drugs) - Your liver function is too impaired Talk to your doctor to see if this trial is right for you.